Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Crosses Above 200 Day Moving Average – What’s Next?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $52.11 and traded as high as $66.96. Global X Genomics & Biotechnology ETF shares last traded at $66.40, with a volume of 24,843 shares changing hands.

Global X Genomics & Biotechnology ETF Trading Down 0.8%

The firm has a fifty day simple moving average of $60.17 and a 200-day simple moving average of $52.11. The stock has a market cap of $132.73 million, a price-to-earnings ratio of -28.38 and a beta of 1.19.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently declared a semiannual dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were issued a $0.0579 dividend. The ex-dividend date was Monday, June 29th. This represents a yield of 20.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -27.35%.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

A hedge fund recently bought a new stake in Global X Genomics & Biotechnology ETF stock. Wealth Management Partners LLC bought a new position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,586 shares of the company’s stock, valued at approximately $244,000. Wealth Management Partners LLC owned 0.50% of Global X Genomics & Biotechnology ETF as of its most recent filing with the Securities and Exchange Commission. 56.95% of the stock is currently owned by institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.